Surgical Innovation Associates
Member
Surgical Innovation Associates (SIA) is committed to bringing better outcomes to patients and lowering cost to the system through “for surgeon, by surgeon” innovation in reconstructive and cosmetic surgery. SIA was originally founded in 2016 by affiliates of Northwestern University Feinberg School of Medicine and Kellogg School of Business in order to develop and commercialize an alternative to certain problematic, cadaver-derived, biologic implants that are being used today.
The company’s first product, DuraSorb™, was developed over the course of 2016-2017, and received FDA clearance for temporary soft tissue support in 2018. SIA has multiple devices in development to improve pre-pectoral breast reconstruction, minimally-invasive facelift, and other techniques.
Headquartered in Chicago, IL, SIA is situated in an active corridor of innovation in the Midwest United States. The company’s proximity to industry, academia and world-leading healthcare institutions is reflected in its strong team and advisory board. This ecosystem is ideal for the rapid translation of concepts into novel devices that incorporate the voice of key stakeholders – regulators, insurers, providers, physicians, and, most importantly, patients.
Surgical Innovation Associates (SIA) is committed to bringing better outcomes to patients and lowering cost to the system through “for surgeon, by surgeon” innovation in reconstructive and cosmetic surgery. SIA was originally founded in 2016 by affiliates of Northwestern University Feinberg School of Medicine and Kellogg School of Business in order to develop and commercialize an alternative to certain problematic, cadaver-derived, biologic implants that are being used today.
